Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Psychedelics Business

News
Mydecine, Top Johns Hopkins Researcher Partner on Study of Psilocybin-Assisted Therapy for Smoking Cessation
09/10/2021

Tom Valentino, Senior Editor

Tom Valentino, Senior Editor
Biopharmaceutical firm Mydecine Innovations Group announced this week that it has partnered with Matthew Johnson, PhD, on a study to evaluate the use of Mydecine’s MYCO-001 compound as part of a smoking cessation program for individuals...
Biopharmaceutical firm Mydecine Innovations Group announced this week that it has partnered with Matthew Johnson, PhD, on a study to evaluate the use of Mydecine’s MYCO-001 compound as part of a smoking cessation program for individuals...
Biopharmaceutical firm Mydecine...
09/10/2021
Psych Congress Network
News
Psychedelics Briefs: Awakn to Study Ketamine Treatment for Gambling Addiction
08/24/2021

Tom Valentino, Senior Editor

Tom Valentino, Senior Editor
Awakn Life Sciences is launching a study on the use of ketamine to treat gambling addiction, while Mydecine and Johns Hopkins have announced plans to collaborate on research of the use of psilocybin for smoking cessation.
Awakn Life Sciences is launching a study on the use of ketamine to treat gambling addiction, while Mydecine and Johns Hopkins have announced plans to collaborate on research of the use of psilocybin for smoking cessation.
Awakn Life Sciences is launching...
08/24/2021
Behavioral Healthcare Executive
News
Psychedelics Briefs: Ketamine One Adds Scent-based VR to Therapy
08/11/2021

Tom Valentino, Senior Editor

Tom Valentino, Senior Editor
Ketamine One has signed a 2-year agreement for the use of OVR Tech’s Inhale Wellness Platform in its psychedelic-assisted therapies, while Awakn Life Sciences has signed a lease for a new clinic in London.
Ketamine One has signed a 2-year agreement for the use of OVR Tech’s Inhale Wellness Platform in its psychedelic-assisted therapies, while Awakn Life Sciences has signed a lease for a new clinic in London.
Ketamine One has signed a 2-year...
08/11/2021
Behavioral Healthcare Executive
News
Psychedelics Briefs: Novamind Opens Utah Clinic, atai Launches Firm to Develop Nose-to-Brain Drug Delivery
08/03/2021

Tom Valentino, Senior Editor

Tom Valentino, Senior Editor
Novamind has finished construction on a psychedelic-assisted psychotherapy and research center in Utah; atai and UniQuest in Australia have launched a firm to develop nose-to-brain drug delivery method for atai’s medications.
Novamind has finished construction on a psychedelic-assisted psychotherapy and research center in Utah; atai and UniQuest in Australia have launched a firm to develop nose-to-brain drug delivery method for atai’s medications.
Novamind has finished...
08/03/2021
Behavioral Healthcare Executive
News
Psychedelics Briefs: Field Trip, Cybin Receive Conditional Stock Listing Approvals; Mydecine Applies for Patent
07/27/2021

Tom Valentino, Senior Editor

Tom Valentino, Senior Editor
Field Trip Health has received conditional approval to list shares on the NASDAQ Global Select Market, and Cybin has received similar approval from the NYSE American stock exchange. Mydecine, meanwhile, has filed for a new patent for...
Field Trip Health has received conditional approval to list shares on the NASDAQ Global Select Market, and Cybin has received similar approval from the NYSE American stock exchange. Mydecine, meanwhile, has filed for a new patent for...
Field Trip Health has received...
07/27/2021
Behavioral Healthcare Executive
News
Awakn Files Patents for MDMA-Derived Entities to Treat Addiction
07/01/2021

Tom Valentino, Senior Editor

Tom Valentino, Senior Editor
Awakn Life Sciences Corp has filed patent applications for a pair of novel MDMA-derived new chemical entities for the treatment of alcohol, opioid and behavioral addictions.
Awakn Life Sciences Corp has filed patent applications for a pair of novel MDMA-derived new chemical entities for the treatment of alcohol, opioid and behavioral addictions.
Awakn Life Sciences Corp has...
07/01/2021
Behavioral Healthcare Executive
News
Psychedelics Briefs: atai Value Surges in Nasdaq Launch; MindMed Announces CEO Transition
06/23/2021

Tom Valentino, Senior Editor

Tom Valentino, Senior Editor
atai Life Sciences saw the value of its shares increase by 40% in their first day of trading on the Nasdaq exchange, putting the company’s value at $3.19 billion after its highly anticipated launch on the U.S. stock market. MindMed has...
atai Life Sciences saw the value of its shares increase by 40% in their first day of trading on the Nasdaq exchange, putting the company’s value at $3.19 billion after its highly anticipated launch on the U.S. stock market. MindMed has...
atai Life Sciences saw the value...
06/23/2021
Behavioral Healthcare Executive
News
Ketamine One Announces Virtual Reality R&D Program
06/09/2021

Tom Valentino, Senior Editor

Tom Valentino, Senior Editor
Ketamine One has announced that its MindScape facility in Houston has launched a research and development program to study the use of immersive virtual reality to enhance patients’ ketamine-assisted treatments, as well as ongoing development...
Ketamine One has announced that its MindScape facility in Houston has launched a research and development program to study the use of immersive virtual reality to enhance patients’ ketamine-assisted treatments, as well as ongoing development...
Ketamine One has announced that...
06/09/2021
Behavioral Healthcare Executive
News
Delic Acquires Ketamine Infusion Centers
06/08/2021

Tom Valentino, Senior Editor

Tom Valentino, Senior Editor
Psychedelic wellness platform Delic Holdings has acquired Ketamine Infusion Centers, which operates ketamine infusion treatment clinics in Phoenix and Bakersfield, California. The
Psychedelic wellness platform Delic Holdings has acquired Ketamine Infusion Centers, which operates ketamine infusion treatment clinics in Phoenix and Bakersfield, California. The
Psychedelic wellness platform...
06/08/2021
Behavioral Healthcare Executive
News
Novamind Projects 225% Increase in Clinic Visits for 2021
06/02/2021
Novamind, a mental health company that specializes in psychedelic medicine, this week announced revenues of $1.85 million for its fiscal quarter ending March 31, a 43% increase over the prior quarter.
Novamind, a mental health company that specializes in psychedelic medicine, this week announced revenues of $1.85 million for its fiscal quarter ending March 31, a 43% increase over the prior quarter.
Novamind, a mental health...
06/02/2021
Behavioral Healthcare Executive

Advertisement

Stay in the Know

Behavioral Healthcare Executive Newsletter

Popular Articles

Buckeye Ranch taps new CEO
03/01/2010
When The Buckeye Ranch named Nicholas Rees as its president and CEO, a few people in Central Ohio’s behavioral healthcare community expressed some
When The Buckeye Ranch named Nicholas Rees as its president and CEO, a few people in Central Ohio’s behavioral healthcare community expressed some
When The Buckeye Ranch named...
03/01/2010
Behavioral Healthcare Executive
News
Acadia buy has new bed potential
05/23/2016
Acadia Healthcare acquired TrustPoint Hospital of Murfreesboro, Tenn., earlier this month, adding 101 beds to its portfolio, plus the potential to grow the facility in the future.
Acadia Healthcare acquired TrustPoint Hospital of Murfreesboro, Tenn., earlier this month, adding 101 beds to its portfolio, plus the potential to grow the facility in the future.
Acadia Healthcare acquired...
05/23/2016
Behavioral Healthcare Executive
What would Ted do now?
01/25/2010
The election in Massachusetts represents but a skirmish in a much longer war. The war is about whether good health will become a basic human right in the United States, much like life, liberty, and the pursuit of happiness. Losing this...
The election in Massachusetts represents but a skirmish in a much longer war. The war is about whether good health will become a basic human right in the United States, much like life, liberty, and the pursuit of happiness. Losing this...
The election in Massachusetts...
01/25/2010
Behavioral Healthcare Executive
Blog
Accelerating the federal response to the opioid epidemic
04/24/2016
Earlier this year, the president asked Congress to appropriate $1.1 billion in new funding to help every American with an opioid use disorder who wants treatment get the help they need.
Earlier this year, the president asked Congress to appropriate $1.1 billion in new funding to help every American with an opioid use disorder who wants treatment get the help they need.
Earlier this year, the president...
04/24/2016
Behavioral Healthcare Executive
Designing an effective nurses` station
11/01/2009
Designing an effective nurses' station for behavioral healthcare environments involves striking a delicate balance. Although openness is critical to
Designing an effective nurses' station for behavioral healthcare environments involves striking a delicate balance. Although openness is critical to
Designing an effective nurses'...
11/01/2009
Behavioral Healthcare Executive

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement